Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

27 Sept 2017

Abstract excerpt

Abstract Purpose: Gene fusions are frequently found in prostate cancer and may result in the formation of unique chimeric amino acid sequences (CASQ) that span the breakpoint of two fused gene products. This study evaluated the potential for fusion-derived CASQs to be a source of tumor neoepitopes, and determined their relationship to patterns of immune signatures in prostate cancer patients. Experimental Design:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28954787
DOI: 10.1158/1078-0432.ccr-17-0618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate CancerPMID 28954787Read ↗

Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer.Semantic proximity Read ↗

INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discoverySemantic proximity Read ↗

Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.Semantic proximity Read ↗

FusionNeoAntigen: a resource of fusion gene-specific neoantigens.Semantic proximity Read ↗

Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.Semantic proximity Read ↗

Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancerSemantic proximity Read ↗

Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer.Semantic proximity Read ↗

Novel Fusion Transcripts Associate with Progressive Prostate CancerSemantic proximity Read ↗

Screening of tumor antigens and immunogenic cell death landscapes of prostate cancer for exploration of mRNA vaccineSemantic proximity Read ↗

RNA-seq Based Transcription Characterization of Fusion Breakpoints as a Potential Estimator for Its Oncogenic Potential.Semantic proximity Read ↗

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.Semantic proximity Read ↗

The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.